ECSP13012892A - IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS - Google Patents

IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS

Info

Publication number
ECSP13012892A
ECSP13012892A ECSP13012892A ECSP13012892A EC SP13012892 A ECSP13012892 A EC SP13012892A EC SP13012892 A ECSP13012892 A EC SP13012892A EC SP13012892 A ECSP13012892 A EC SP13012892A
Authority
EC
Ecuador
Prior art keywords
treatment
triazins
imidazo
neurological disorders
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher J Helal
Thomas Allen Chappie
John Michael Humphrey
Patrick Robert Verhoest
Eddie Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012892(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP13012892A publication Critical patent/ECSP13012892A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y a sales de los mismos farmacéuticamente aceptables, a procedimientos para la preparación de, a intermedios usados en la preparación de, y composiciones que contienen dichos compuestos y a los usos de dichos compuestos como un procedimiento para el tratamiento, de una enfermedad o afección seleccionada del grupo que consiste en trastornos del sistema nervioso central, trastornos cognitivos, esquizofrenia, demencia y otros trastornos, en un mamífero.
ECSP13012892 2011-02-23 2013-09-23 IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS ECSP13012892A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161445617P 2011-02-23 2011-02-23

Publications (1)

Publication Number Publication Date
ECSP13012892A true ECSP13012892A (es) 2013-10-31

Family

ID=45755439

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012892 ECSP13012892A (es) 2011-02-23 2013-09-23 IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS

Country Status (31)

Country Link
US (2) US8598155B2 (es)
EP (1) EP2681218A1 (es)
JP (1) JP5543039B2 (es)
KR (1) KR101548443B1 (es)
CN (1) CN103391941A (es)
AP (1) AP2013007070A0 (es)
AR (1) AR085304A1 (es)
AU (1) AU2012221828C1 (es)
BR (1) BR112013021366A2 (es)
CA (1) CA2825699A1 (es)
CL (1) CL2013002125A1 (es)
CO (1) CO6751271A2 (es)
CR (1) CR20130371A (es)
CU (1) CU20130107A7 (es)
DO (1) DOP2013000194A (es)
EA (1) EA022586B1 (es)
EC (1) ECSP13012892A (es)
GT (1) GT201300206A (es)
IL (1) IL227716A0 (es)
MA (1) MA34922B1 (es)
MX (1) MX2013009684A (es)
NI (1) NI201300071A (es)
PE (1) PE20140236A1 (es)
PH (1) PH12013501556A1 (es)
SG (1) SG192576A1 (es)
TN (1) TN2013000349A1 (es)
TW (1) TWI469983B (es)
UA (1) UA106692C2 (es)
UY (1) UY33916A (es)
WO (1) WO2012114222A1 (es)
ZA (1) ZA201306348B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2013007070A0 (en) * 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
AP2015008843A0 (en) 2013-05-02 2015-11-30 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
WO2015096651A1 (en) 2013-12-23 2015-07-02 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
EP3134413B1 (en) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
CN104525240A (zh) * 2014-12-10 2015-04-22 河北工业大学 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
US10647727B2 (en) 2015-06-25 2020-05-12 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
UA122423C2 (uk) * 2015-11-02 2020-11-10 Янссен Фармацевтика Нв [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
MA46690A (fr) 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
KR20190071721A (ko) 2016-11-02 2019-06-24 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
UA125302C2 (uk) 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
PT3713572T (pt) 2017-11-23 2025-08-28 Oslo Univ Hospital Hf Tratamento da taquicardia
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
WO2020086650A2 (en) * 2018-10-23 2020-04-30 Intra-Cellular Therapies, Inc. Novel compounds
US11492362B1 (en) 2022-02-17 2022-11-08 King Abdulaziz University Pyridine derivatives for the treatment of hyperproliferative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4035893A (en) * 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2005041957A1 (en) * 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
HRP20090495T1 (hr) 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
CA2591991C (en) * 2005-01-05 2013-11-19 Altana Pharma Ag Triazolophthalazines
EA012211B1 (ru) 2005-01-07 2009-08-28 Пфайзер Продактс Инк. Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
ES2436877T3 (es) 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
US7659274B2 (en) 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US7683575B2 (en) 2007-07-18 2010-03-23 Tesla Motors, Inc. Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack
JP2011515410A (ja) 2008-03-19 2011-05-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 塩の形のｍＴＯＲ阻害剤
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
EP2451792A4 (en) 2009-07-09 2013-03-06 Osi Pharmaceuticals Llc PROCESS FOR THE PRODUCTION OF SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO- [1,2,4] TRIAZINES
JP5714030B2 (ja) 2010-02-03 2015-05-07 インサイト コーポレーションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン
AP2013007070A0 (en) * 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders

Also Published As

Publication number Publication date
CL2013002125A1 (es) 2013-12-20
WO2012114222A1 (en) 2012-08-30
US9200000B2 (en) 2015-12-01
PH12013501556A1 (en) 2017-10-25
DOP2013000194A (es) 2014-01-31
SG192576A1 (en) 2013-09-30
AR085304A1 (es) 2013-09-18
TN2013000349A1 (fr) 2015-01-20
JP5543039B2 (ja) 2014-07-09
JP2014506589A (ja) 2014-03-17
EA201390971A1 (ru) 2014-02-28
NI201300071A (es) 2014-02-12
US20140066622A1 (en) 2014-03-06
UY33916A (es) 2012-09-28
CU20130107A7 (es) 2013-09-27
EA022586B1 (ru) 2016-01-29
CA2825699A1 (en) 2012-08-30
KR20130132612A (ko) 2013-12-04
CN103391941A (zh) 2013-11-13
MX2013009684A (es) 2013-10-28
TWI469983B (zh) 2015-01-21
CO6751271A2 (es) 2013-09-16
NZ613373A (en) 2015-04-24
BR112013021366A2 (pt) 2016-09-13
UA106692C2 (uk) 2014-09-25
TW201247673A (en) 2012-12-01
CR20130371A (es) 2013-09-18
GT201300206A (es) 2015-02-19
US8598155B2 (en) 2013-12-03
MA34922B1 (fr) 2014-02-01
PE20140236A1 (es) 2014-03-14
ZA201306348B (en) 2014-04-30
IL227716A0 (en) 2013-09-30
AU2012221828B2 (en) 2015-05-28
AU2012221828C1 (en) 2015-10-01
KR101548443B1 (ko) 2015-08-28
EP2681218A1 (en) 2014-01-08
AP2013007070A0 (en) 2013-08-31
US20120214791A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
CU20130107A7 (es) IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
PE20150706A1 (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
AR123407A1 (es) Un proceso para la fabricación de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octahidro-[1,3]dioxolo[4’,5’:5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolina-6,7-diol
MX2012004157A (es) 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
MX2015011618A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso.
CL2009000975A1 (es) Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer.
ECSP10010608A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
DOP2010000309A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
MX2014003169A (es) Ligandos del receptor ep1.
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
MX2020004190A (es) Amidas de imidazopiridina sustituidas y su uso.
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
CO6592112A2 (es) Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciòn
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
BR112014012031A2 (pt) derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1
UY34281A (es) "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina